Click here to close now.



Welcome!

Microsoft Cloud Authors: Pat Romanski, Elizabeth White, Liz McMillan, Mihai Corbuleac, David Bermingham

News Feed Item

Helix BioPharma Corp. Announces Fiscal 2013 Q1 Results

AURORA, ON -- (Marketwire) -- 12/12/12 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results and research and development update for the quarter ended October 31, 2012.

HIGHLIGHTS DURING THE QUARTER

During Q1 of fiscal 2013, the Company:

  • Announced first patient enrollment and dosing in the European Phase I/II clinical study of L-DOS47 in Poland;

  • Continued its cost reduction initiatives, including a further downsizing of staff in Saskatoon along with the decision to close the Saskatoon facility, effective November 30, 3012;

  • Extended the expiry date of warrants issued in on September 8, 2009 for an additional six months, from September 7, 2012 to March 7, 2013; and

  • The Company's cash and cash equivalents, as at October 31, 2012 total $3,313,000 and the Company continues to pursue various options to raise cash.

SUBSEQUENT EVENT

On December 10, 2012, the Company announced that it has entered into a definitive agreement for the sale of its Rivex Pharma division to Pharmscience Inc. for gross cash proceeds of up to $8.5 million (the "Rivex Transaction"). The Rivex Transaction has been unanimously approved by the Company's board of directors and is subject to the approval of Helix's shareholders and certain other customary closing conditions. The board of directors has called an annual general and special meeting of shareholders to be held on January 24, 2013, at which the Company will seek shareholder approval of the Rivex Transaction. If approved by shareholders, the Company expects that the Rivex Transaction will close in late January, 2013.

RESULTS FROM OPERATIONS

Three month period ended October 31, 2012 compared to the same period in the previous year

Loss for the period
The Company recorded a loss of $2,077,000 and $3,244,000, respectively for the fiscal quarters ended October 31, 2012 and 2011 for a loss per common share of $0.03 and $0.05, respectively.

The lower loss in the fiscal quarter ended October 31, 2012 compared to the three month period ended October 31, 2011 is due to lower research & development and operating, general and administration expenses along with lower product revenue.

Revenues
Revenues totalled $882,000 and $1,122,000 for the fiscal quarters ended October 31, 2012 and 2011, respectively and represents a decrease of $240,000 (21.4%) when compared to the three month period ended October 31, 2011. The entire decrease is represented by a decrease in product revenue.

The decrease in product revenues is the result of discontinuing Normacol® in late fiscal 2012 in addition to lower sales volumes for Orthovisc® and Klean-Prep™. Sales of Orthovisc® were hindered in the quarter as a result of supplier backorders.

Cost of sales and margins
Cost of sales totalled $355,000 and $456,000 respectively for the fiscal quarters ended October 31, 2012 and 2011. As a percentage of product revenues, cost of sales were 40.2% and 40.6% for the fiscal quarters ended October 31, 2012 and 2011, respectively.

Research & development
Research and development costs for the fiscal quarters ended October 31, 2012 and 2011 totalled $1,608,000 and $2,111,000 respectively.

L-DOS47 research and development costs for the fiscal quarters ended October 31, 2012 and 2011 totalled $874,000 and $999,000, respectively. For the fiscal quarter ended October 31, 2011, the L-DOS47 research and development expenditures reflect expenditures associated with the preparation for commencement of a Polish Phase I/II clinical study and a U.S. Phase I clinical study with L-DOS47. On May 14, 2012 the Company announced the commencement of clinical site initiations and patient recruitment activities of its Polish Phase I/II clinical study in Poland. On October 23, 2012, the Company announced that the first patient has been enrolled and first dose administered in its Polish Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland.

Topical Interferon Alpha-2b research and development expenses for the fiscal quarters ended October 31, 2012 and 2011 totalled $450,000 and $652,000, respectively. The Company's research and development expenditures associated with Topical Interferon Alpha-2 for the current fiscal quarter have been limited and mainly reflect overhead costs associated with supporting the program. In the fiscal fourth quarter of 2012, the Company initiated a downsizing of the staff in the Saskatoon laboratory and in addition postponed the completion of work necessary to resolve the Medicines and Healthcare Regulatory Authority ("MHRA") approval conditions associated with Helix's December 2011 Phase III clinical trial application filing. Under the terms of this conditional approval, the Company must submit additional details, for approval by MHRA before proceeding with the Phase III trial, in the event the Company wishes to potentially extend the shelf life of its product beyond that which was stipulated in its clinical trial application. The Company proceeded with additional staff downsizing at its Saskatoon laboratory in October 2012, including a decision to close the Saskatoon laboratory by the end of November 2012. Costs associated with the downsizing were charged in the current quarter.

The Company also incurred corporate research and development expenses. Corporate research and development expenses totalling $284,000 and $460,000 respectively for the fiscal quarters ended October 31, 2012 and 2011. The lower expenses can be attributed to a reduction in payroll expense associated with headcount reductions of corporate research and development employees during fiscal 2012 in addition to a reduction in travel and consulting expenses.

Operating, general & administration
Operating, general and administration expenses for the fiscal quarters ended October 31, 2012 and 2011 totalled $764,000 and $1,275,000 respectively and represents a decrease of $511,000 (40.1%) when compared to the fiscal 2012 quarter. Lower operating, general and administration expenses are the result of ongoing cost cutting measures by the Company, with the most significant reductions related to lower legal and audit fees as a result of the Company having voluntarily surrendered its listing on the NYSE-MKT exchange in the United States, stock-based compensation expense, reduced headcount and investor relations activities.

Sales and marketing
Sales and marketing expenses for the fiscal quarters ended October 31, 2012 and 2011 totalled $204,000 and $298,000 and represents a decrease of $94,000 (31.5%) when compared to the fiscal 2012 quarter. The lower expenses can be attributed to lower promotion and advertising expenses, regulatory and compliance costs for the most recent quarter compared to the same period in the prior year, lower sales commissions as a result of lower sales and decreased stock-based compensation expense.

2012 AGM, Special Committee and Settlement
Expenses relating to the special committee of independent directors (the "Special Committee") formed in connection with the Company's contested annual general meeting of shareholders held on January 30, 2012 (the "2012 AGM") and the subsequent settlement agreement entered into with certain of the concerned shareholders (the "Settlement") for the fiscal quarters ended October 31, 2012 and 2011 totalled $nil and $245,000, respectively. The expense amount included in Q1 of fiscal 2012 primarily reflects legal expenses incurred by the Company.

Finance income and expense
Finance income and expense combined for the fiscal quarters ended October 31, 2012 and 2011 totalled $6,000 and $44,000 respectively. The decrease in interest income in Q1 of fiscal 2013 reflects lower cash balances.

Foreign exchange loss
Foreign exchange for the fiscal quarters ended October 31, 2012 and 2011 reflects losses of $34,000 and $25,000 respectively. Foreign exchange gains and losses result mainly from the sales and purchases that are denominated in currencies other than functional currencies. In addition, they can arise from purchase transactions, as well as recognized monetary financial assets and liabilities denominated in foreign currencies.

CASH FLOW

Operating activities
Cash used in operating activities for the three month periods ended October 31, 2012 and 2011 totalled $1,502,000 and $1,391,000 respectively and includes a net loss of $2,077,000 (2011 - $3,244,000) with significant adjustments in operating activities related to stock-based compensation of $96,000 (2011 - $386,000); depreciation of property, plant and equipment of $103,000 (2011 - $174,000); and $348,000 (2011 - $1,236,000) net increase to non-cash working capital.

Financing activities
Cash provided from financing activities for the three month periods ended October 31, 2012 and 2011 totalled $nil and $43,000 respectively and is attributable to proceeds from the exercise of stock options.

Investing activities
Investing activities for the three month periods ended October 31, 2012 and 2011 totalled $13,000 and $17,000 respectively and mainly represents replacement of IT assets in both fiscal periods.

LIQUIDITY AND CAPITAL RESOURCES

Since inception, the Company has financed its operations from public and private sales of equity, proceeds received upon the exercise of warrants and stock options, and, to a lesser extent, from interest income from funds available for investment, government grants, investment tax credits, and revenues from distribution, licensing and contract services. Since the Company does not have net earnings from its operations, the Company's long-term liquidity depends on its ability to access the capital markets, which depends substantially on the success of the Company's ongoing research and development programs, as well as economic conditions relating to the state of the capital markets generally.

At October 31, 2012, the Company had cash and cash equivalents totaling $3,313,000 (July 31, 2012 - $4,862,000). The total number of common shares issued as at October 31, 2012 was 67,226,337 (July 31, 2012 - 67,226,337).

The Company's cash resources have been severely strained by the costs incurred in connection with activities in fiscal 2012 including the 2012 AGM, Special Committee and Settlement Agreement. As a result, the Company's cash position of $3,313,000 as at October 31, 2012 is insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months. Various cost-cutting and cost-deferral measures have been initiated in order to extend the Company's cash resources, permitting it more time to seek additional financing. By prioritizing the monotherapy arm of the Company's Polish Phase I/II clinical study for L-DOS47 and pushing out the non-monotherapy arms, coupled with certain cost-cutting and cost-deferral measures which have already taken place and are ongoing, the Company believes its current cash resources may not be sufficient to continue operations beyond March 2013.

Securing additional financing is of utmost priority to the Company. However, there is no assurance that additional financing can be obtained in a timely manner or at all.

Equity financing has historically been the Company's primary source of funding, however, the market for equity financings for companies such as Helix is challenging, especially in the current economic environment. While the Company has been able to raise equity financing in recent years, there can be no assurance that additional funding by way of equity financing will continue to be available. Any additional equity financing, if secured, would result in dilution to the existing shareholders which may be significant. The Company may also seek additional funding from or through other sources, including technology licensing, co-development collaborations, mergers and acquisitions, joint ventures, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products or result in significant dilution to existing shareholders. There can be no assurance, however, that any alternative sources of funding will be available. The failure of the Company to obtain additional financing on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research, development and/or marketing programs, including clinical trials, further reducing overhead, or monetizing non-core assets, any of which could impair the current and future value of the business or cause the Company to consider ceasing operations and undergoing liquidation.

Given the Company's conclusion about the insufficiency of its cash reserves, significant doubt may be cast about the Company's ability to continue operating as a going concern. The continuation of the Company as a going concern for the foreseeable future depends mainly on raising sufficient capital, and in the interim, reducing, where possible, operating expenses (including making changes to the Company's research and development plans), including the delay of one or more of the Company's research and development programs, further reducing overhead and the possible disposition of assets (see Subsequent Event, above).

The Company's condensed unaudited interim consolidated statement of net loss and comprehensive loss for the three month periods ending October 31, 2012 and 2011 and the condensed unaudited interim consolidated statement of cash flows for the three month periods ending October 31, 2012 and 2011 are summarized below:

The Company's condensed unaudited interim consolidated statement of financial position as at October 31, 2012 and July 31, 2012 are summarized below:


Consolidated Statement of Net Loss and Comprehensive Loss
For the three month periods ended October 31, 2012 and 2011
(thousand $, except for per share data)

                                                               Three months
                                                           ended October 31
                                                           2012        2011
                                                     ----------  ----------
Revenue:
  Product revenue                                           882       1,122

Expenses:
  Cost of sales                                             355         456
  Research and development                                1,608       2,111
  Operating, general and administration                     764       1,275
  Sales and marketing                                       204         298
  Special committee and settlement                            -         245
                                                     ----------  ----------
                                                          2,931       4,385

Loss before finance items                                (2,049)     (3,263)

Finance items:
  Finance income                                             10          49
  Finance expense                                            (4)         (5)
  Foreign exchange (loss)                                   (34)        (25)
                                                     ----------  ----------
                                                            (28)         19

                                                     ----------  ----------
Net loss & total comprehensive loss                      (2,077)     (3,244)
                                                     ==========  ==========

    Loss per share:
      Basic & diluted                                     (0.03)      (0.05)
                                                     ==========  ==========



Consolidated Statements of Cash Flows
For the three month periods ended October 31, 2012 and 2011
(thousand $)

                                                               Three months
                                                           ended October 31
                                                           2012        2011
                                                     ----------  ----------

Cash provided by (used in):
    Loss for the period                                  (2,077)     (3,244)

Items not involving cash:
  Depreciation of property, plant and equipment             103         174
  Deferred lease credit                                      (6)         (7)
  Stock-based compensation                                   96         386
  Stock-based consideration                                   -          39
  Foreign exchange loss (gain)                               34          25
                                                     ----------  ----------
                                                            227         617

Change in non-cash working capital                          348       1,236
                                                     ----------  ----------

Operating activities                                     (1,502)     (1,391)

Financing activities                                          -          43

Investing activities                                        (13)        (17)

Effect of exchange rate changes on cash and cash
 equivalents                                                (34)        (25)

Cash and cash equivalents:
  Increase/(decrease)                                    (1,549)     (1,390)
  Beginning of the period                                 4,862      19,044
                                                     ----------  ----------
  End of the period                                       3,313      17,654
                                                     ==========  ==========



Consolidated Statement of Financial Position (thousand $)

                                                     October 31,    July 31,
                                                            2012        2012
                                                     ----------- -----------

Non current assets                                         1,403       1,493

Current assets:
  Prepaids                                                   141         107
  Inventory                                                  305         421
  Accounts receivable                                        666         733
  Cash and cash equivalents                                3,313       4,862
                                                     ----------- -----------
                                                           4,425       6,123

                                                     ----------- -----------
Total assets                                               5,828       7,616
                                                     =========== ===========

Shareholders' equity                                       4,243       6,224

Non current liabilities                                       17          23

Current liabilities:
  Deferred lease credit                                       25          25
  Accrued liabilities                                        799         694
  Accounts payable                                           744         650
                                                     ----------- -----------
                                                           1,568       1,369

Total liabilities                                          1,585       1,392

                                                     ----------- -----------
Total liabilities and shareholders' equity                 5,828       7,616
                                                     =========== ===========


The Company's condensed unaudited interim consolidated financial statements and management's discussion and analysis are being filed with the Canadian Securities Administrators and will be available under the Company's profile on SEDAR at www.sedar.com as well as on the Company's website at www.helixbiopharma.com. Shareholders have the ability to receive a hard copy of the Company's unaudited condensed interim consolidated financial statements free of charge upon request at the address below.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the focus of the Company on its two drug candidates, L-DOS47 and Topical Interferon Alpha-2b (cervical lesions indication); and other information in future periods.

Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's growth and future prospects being dependent on the success of one or both of L-DOS47 and Topical Interferon Alpha-2b; (iii) the Company's priority continuing to be L-DOS47; (iv) the Company's development programs for Topical Interferon Alpha-2b, DOS47 and L-DOS47; (v) future expenditures, insufficiency of the Company's current cash resources and the need for financing and cost-cutting and/or cost-deferral measures; (vi) future financing requirements, the seeking of additional funding and anticipated future revenue and operating losses; and (vii) the completion of the Rivex Transaction, including the satisfaction of the conditions to closing the Rivex Transaction, and the anticipated timelines for completing the Rivex Transaction. Forward-looking statements can further be identified by the use of forward-looking terminology such as "expects", "plans", "designed to", "potential", "is developing", "believe", "intended", "continues", "opportunities", "anticipated", "2012", "2013", "next", ongoing", "pursue", "to seek", "proceed", "objective", "estimate", "future", "wish", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47 and Topical Interferon Alpha-2b (low-grade cervical lesions); that sufficient financing will be obtained in a timely manner to allow the Company to continue operations; that sufficient cost-deferral and/or cost-cutting measures will be taken; the timely provision of services and supplies, including Interferon alpha-2b raw materials, or other performance of contracts by third parties; future revenue and costs; the absence of any material changes in business strategy or plans, other than the implementation of cost-deferral and/or cost-cutting measures; the timely receipt of required regulatory approvals, and strategic partner support; that the Rivex Transaction will be completed on the anticipated timelines; that the conditions precedent set forth in the definitive purchase agreement, including the condition that Helix's shareholders approve the Rivex Transaction, are satisfied or waived within the timelines required by the definitive purchase agreement; and that there will be no changes in market, economic, industry or regulatory conditions.

The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that the Company may be unsuccessful in its cost-cutting and cost-deferral initiatives; clinical trials may not commence or complete within anticipated timelines or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development or distribution activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; that the Rivex Transaction is not completed on the anticipated timelines or at all; that the conditions precedent set forth in the definitive purchase agreement, including the condition that the Company's shareholders approve the Rivex Transaction are not satisfied or waived within the timelines required by the definitive purchase agreement; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Helix's Annual Report, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed with the Canadian Securities Administrators from time to time at www.sedar.com. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effi...
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discussed how businesses can gain an edge over competitors by empowering consumers to take control through IoT. He cited examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He also highlighted how IoT can revitalize and restore outdated business models, making them profitable ...
There are several IoTs: the Industrial Internet, Consumer Wearables, Wearables and Healthcare, Supply Chains, and the movement toward Smart Grids, Cities, Regions, and Nations. There are competing communications standards every step of the way, a bewildering array of sensors and devices, and an entire world of competing data analytics platforms. To some this appears to be chaos. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Bradley Holt, Developer Advocate a...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, discussed how research has demonstrated the value of Machine Learning in delivering next generation analytics to imp...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
Connected devices and the industrial internet are growing exponentially every year with Cisco expecting 50 billion devices to be in operation by 2020. In this period of growth, location-based insights are becoming invaluable to many businesses as they adopt new connected technologies. Knowing when and where these devices connect from is critical for a number of scenarios in supply chain management, disaster management, emergency response, M2M, location marketing and more. In his session at @Th...
Basho Technologies has announced the latest release of Basho Riak TS, version 1.3. Riak TS is an enterprise-grade NoSQL database optimized for Internet of Things (IoT). The open source version enables developers to download the software for free and use it in production as well as make contributions to the code and develop applications around Riak TS. Enhancements to Riak TS make it quick, easy and cost-effective to spin up an instance to test new ideas and build IoT applications. In addition to...
When people aren’t talking about VMs and containers, they’re talking about serverless architecture. Serverless is about no maintenance. It means you are not worried about low-level infrastructural and operational details. An event-driven serverless platform is a great use case for IoT. In his session at @ThingsExpo, Animesh Singh, an STSM and Lead for IBM Cloud Platform and Infrastructure, will detail how to build a distributed serverless, polyglot, microservices framework using open source tec...
Apixio Inc. has raised $19.3 million in Series D venture capital funding led by SSM Partners with participation from First Analysis, Bain Capital Ventures and Apixio’s largest angel investor. Apixio will dedicate the proceeds toward advancing and scaling products powered by its cognitive computing platform, further enabling insights for optimal patient care. The Series D funding comes as Apixio experiences strong momentum and increasing demand for its HCC Profiler solution, which mines unstruc...
IoT offers a value of almost $4 trillion to the manufacturing industry through platforms that can improve margins, optimize operations & drive high performance work teams. By using IoT technologies as a foundation, manufacturing customers are integrating worker safety with manufacturing systems, driving deep collaboration and utilizing analytics to exponentially increased per-unit margins. However, as Benoit Lheureux, the VP for Research at Gartner points out, “IoT project implementers often ...
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his Day 2 Keynote at @ThingsExpo, Henrik Kenani Dahlgren, Portfolio Marketing Manager at Ericsson, discussed how to plan to cooperate, partner, and form lasting all-star teams to change t...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Presidio has received the 2015 EMC Partner Services Quality Award from EMC Corporation for achieving outstanding service excellence and customer satisfaction as measured by the EMC Partner Services Quality (PSQ) program. Presidio was also honored as the 2015 EMC Americas Marketing Excellence Partner of the Year and 2015 Mid-Market East Partner of the Year. The EMC PSQ program is a project-specific survey program designed for partners with Service Partner designations to solicit customer feedbac...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...